JP2024546641A5 - - Google Patents

Info

Publication number
JP2024546641A5
JP2024546641A5 JP2024533092A JP2024533092A JP2024546641A5 JP 2024546641 A5 JP2024546641 A5 JP 2024546641A5 JP 2024533092 A JP2024533092 A JP 2024533092A JP 2024533092 A JP2024533092 A JP 2024533092A JP 2024546641 A5 JP2024546641 A5 JP 2024546641A5
Authority
JP
Japan
Prior art keywords
composition according
nucleic acid
acid molecules
composition
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/052207 external-priority patent/WO2023107593A2/en
Publication of JP2024546641A publication Critical patent/JP2024546641A/ja
Publication of JP2024546641A5 publication Critical patent/JP2024546641A5/ja
Pending legal-status Critical Current

Links

JP2024533092A 2021-12-09 2022-12-08 免疫細胞へのインビボ送達 Pending JP2024546641A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287725P 2021-12-09 2021-12-09
US63/287,725 2021-12-09
PCT/US2022/052207 WO2023107593A2 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Publications (2)

Publication Number Publication Date
JP2024546641A JP2024546641A (ja) 2024-12-26
JP2024546641A5 true JP2024546641A5 (cg-RX-API-DMAC7.html) 2026-01-07

Family

ID=86731192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533092A Pending JP2024546641A (ja) 2021-12-09 2022-12-08 免疫細胞へのインビボ送達

Country Status (4)

Country Link
EP (1) EP4444361A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546641A (cg-RX-API-DMAC7.html)
AU (1) AU2022407035A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023107593A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
WO2024026284A2 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
CN117343908B (zh) * 2023-12-05 2024-02-09 南京大学 一种通过真菌精准激活的car-t细胞、制备方法、应用及药物组合物
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars
EP4118098A4 (en) * 2020-03-11 2024-06-12 The Trustees of The University of Pennsylvania METHOD AND COMPOSITION FOR GENE DELIVERY USING AN MANIPULATED VIRUS PARTICLE
US20240245805A1 (en) * 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
MX2022015888A (es) * 2020-06-26 2023-03-28 Carisma Therapeutics Inc Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.

Similar Documents

Publication Publication Date Title
JP7308000B2 (ja) Vegf-aポリペプチドをコードする改変rnaを送達するための脂質ナノ粒子
JP7285220B2 (ja) 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
JP6990176B2 (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
JP2023522249A5 (cg-RX-API-DMAC7.html)
Abu Abed Gene therapy avenues and COVID-19 vaccines
JP2023523580A (ja) コロナウイルスワクチン
EP3317411B1 (en) Atp-binding cassette family coding polyribonucleotides and formulations thereof
KR20240035836A (ko) 지질 나노-에멀젼 입자에 흡착된 rna 및 그 제제
CN118434436A (zh) 免疫刺激性mrna组合物及其用途
US20230149535A1 (en) Vaccines for coronavirus and methods of using the same
Huang et al. Advances in development of mRNA-based therapeutics
WO2023113016A1 (en) Efficient vaccine
WO2021042944A1 (zh) 肌肉靶向的微环dna基因治疗
CN117567571A (zh) 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用
EP4342993A1 (en) Hpv infectious disease vaccine
JP2026500282A (ja) インフルエンザウイルス様粒子をコードするmRNA
US11517611B2 (en) Methods of treating viral infection with a composition comprising IL-18 and IL-22
Haaijer Immunogenic versus tolerogenic mRNA Vaccines
WO2025253381A1 (en) Cyclic gmp-amp synthase variants and use thereof
EP4722367A1 (en) Mrna structure platform for protein expression with high efficiency
EP4683666A1 (en) Peg targeting compounds for delivery of therapeutics
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
WO2024197310A1 (en) Peg targeting compounds for delivery of therapeutics
WO2026104647A1 (en) Vaccine
CN117886903A (zh) 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用